BTBR Ob/Ob Mutant Mice Model Progressive Diabetic Nephropathy


*Department of Pathology and §Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington; †Division of Nephrology, University of Regensburg, Regensburg, Germany; ‡Division of Nephrology, University of Aachen, Aachen, Germany; and ‖Department of Biochemistry, University of Wisconsin, Madison, Wisconsin

ABSTRACT

There remains a need for robust mouse models of diabetic nephropathy (DN) that mimic key features of advanced human DN. The recently developed mouse strain BTBR with the ob/ob leptin-deficiency mutation develops severe type 2 diabetes, hypercholesterolemia, elevated triglycerides, and insulin resistance, but the renal phenotype has not been characterized. Here, we show that these obese, diabetic mice rapidly develop morphologic renal lesions characteristic of both early and advanced human DN. BTBR ob/ob mice developed progressive proteinuria beginning at 4 weeks. Glomerular hypertrophy and accumulation of mesangial matrix, characteristic of early DN, were present by 8 weeks, and glomerular lesions similar to those of advanced human DN were present by 20 weeks. By 22 weeks, we observed an approximately 20% increase in basement membrane thickness and a >50% increase in mesangial matrix. Diffuse mesangial sclerosis (focally approaching nodular glomerulosclerosis), focal arteriolar hyalinosis, mesangiolysis, and focal mild interstitial fibrosis were present. Loss of podocytes was present early and persisted. In summary, BTBR ob/ob mice develop a constellation of abnormalities that closely resemble advanced human DN more rapidly than most other murine models, making this strain particularly attractive for testing therapeutic interventions.


Diabetic nephropathy (DN) is the largest single cause of ESRD in the United States, accounting for nearly half of the patients who enter the dialysis patient population each year and currently accounting for 45% of prevalent kidney failure in the United States.1–4 Although both type 1 and type 2 diabetes lead to DN, the current epidemic of DN is due to type 2 diabetes; however, understanding the mechanisms that produce the constellation of clinical and pathologic alterations that define DN in humans remains very incomplete, in part because clinical DN is a slowly progressive disease, and relevant animal models that produce this constellation of pathologic and clinical abnormalities have important limitations. Mice rendered hyperglycemic by administration of streptozotocin (STZ) or through genetic predisposition such as the db/db mouse can develop some features of DN, most notably glomerular mesangial expansion, but do so only over prolonged periods and do not progress to ESRD.5–9 Most murine models to date have failed to develop reliably marked mesangial expansion or the...
distinctive nodular glomerulosclerosis with mesangiolysis or hyalinosis characteristic of human disease. Furthermore, the extent of loss or preservation of podocytes, currently accepted to be important in human DN, is generally unknown in each of these models. Thus, the availability of a murine model of DN that better resembles its human counterpart and in particular develops glomerular lesions of podocyte loss, mesangiolysis, and severe sclerosis would be a new and significant resource for mechanistic investigations of DN and to test potential therapeutic interventions.

A mouse model of insulin resistance that develops in the progeny of the BTBR (black and tan, brachyuric) mouse strain crossed with C57BL/6 mice has been characterized by Attie and colleagues. BTBR mice are naturally hyperinsulinemic when compared with C57BL/6 mice, and BTBR × C57BL/6 F1 mice are substantially insulin resistant. Mice homozygous for the ob/ob mutation lack the hormone leptin. When this mutation is on the C57BL/6 background, mice become obese but are only mildly hyperglycemic and do not develop renal lesions characteristic of human diabetes. When the ob/ob mutation is placed on a BTBR background, the mice are initially insulin resistant with elevated insulin levels and pancreatic islet hypertrophy and have marked hyperglycemia by 6 weeks of age. The C57BL/6 and BTBR strains, when made obese by introduction of the ob/ob mutation, differ significantly in their diabetes susceptibility; C57BL/6 ob/ob mice are insulin resistant but relatively diabetes resistant, whereas BTBR ob/ob mice are insulin resistant and develop severe diabetes. BTBR ob/ob mice maintain sustained hyperglycemia (blood glucose 350 to 400 mg/dl) and are largely resistant to the blood glucose-lowering effect of insulin administration. Although there are some sex differences in the diabetic disease manifestations, particularly in the early course of the disease, both sexes are ultimately affected by severe diabetes. In this study, we characterize the development of DN in both the male and female BTBR ob/ob mice.

RESULTS

Blood and Urine Parameters

Both male and female BTBR ob/ob mice have significantly increased blood glucose levels and body weight detectable at 8 weeks when compared with heterozygous BTBR ob+/- and BTBR wild-type (WT) littermates (Table 1, Supplemental Figure 1). Male mice progressed to somewhat higher blood glucose levels, averaging 399.0 ± 38.8 mg/dl at 22 weeks compared with female mice with an average of 333.0 ± 46.3 mg/dl (Table 1). Compared with obese C57BL/6 ob/ob mice, BTBR ob/ob mice have significantly higher blood glucose levels (Table 1). Despite the early hyperglycemia, the growth rate of BTBR ob/ob mice was similar to that of nondiabetic C57BL/6 ob/ob mice (data not shown). Serum triglyceride, cholesterol, and blood urea nitrogen (BUN) levels were elevated in both male and female

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C57BL/6</th>
<th>C57BL/6 ob/ob</th>
<th>BTHR</th>
<th>BTBR ob/ob</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg/dl)</td>
<td>159.5 ± 7.2</td>
<td>133 ± 10.2</td>
<td>29.0 ± 7.0</td>
<td>333 ± 46.3a,b</td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>26 ± 2.9</td>
<td>27.9 ± 3.0</td>
<td>151.5 ± 26.3a,b</td>
<td>0.256 ± 0.069</td>
</tr>
<tr>
<td>Creatinine (HPLC; mg/dl)</td>
<td>59.8 ± 8.2e</td>
<td>93.8 ± 5.5p</td>
<td>96.3 ± 31.8e</td>
<td>79 ± 10.5b</td>
</tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>65.0 ± 5.0</td>
<td>50.8 ± 4.8</td>
<td>96.9 ± 139.9a,b</td>
<td>79 ± 10.5b</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>63.8 ± 8.8a</td>
<td>64.9 ± 4.4p</td>
<td>96.9 ± 139.9a,b</td>
<td>79 ± 10.5b</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>195.9 ± 29.1</td>
<td>94.1 ± 18.9a</td>
<td>96.9 ± 139.9a,b</td>
<td>79 ± 10.5b</td>
</tr>
<tr>
<td>ACR (μg/mg)</td>
<td>54.0 ± 20.0</td>
<td>21.32 ± 7.8</td>
<td>248.7 ± 47.1a,b</td>
<td></td>
</tr>
<tr>
<td>Albumin, 24-hour (μg)</td>
<td>9.1 ± 3.7</td>
<td>20.0 ± 2.9</td>
<td>20.0 ± 2.9</td>
<td>248.7 ± 47.1a,b</td>
</tr>
</tbody>
</table>

Controls include C57BL/6 mice with and without the ob/ob mutation. ACR, albumin-creatinine ratio; ND, not done (sera from the 20- to 22-week-old C57BL/6 and C57BL/6 ob/ob mice had been exhausted).

Table 1. Representative laboratory data for BTBR ob/ob mice and C57BL/6 control mice all between 20 and 22 weeks of age (n = 6)

Male

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C57BL/6</th>
<th>C57BL/6 ob/ob</th>
<th>BTHR</th>
<th>BTBR ob/ob</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg/dl)</td>
<td>159.5 ± 10.5</td>
<td>245.4 ± 33.7a</td>
<td>147 ± 16.4</td>
<td>399 ± 38.8a,b</td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>36.7 ± 2.1</td>
<td>19.5 ± 5.0b</td>
<td>35.0 ± 11.3a</td>
<td>0.148 ± 0.024</td>
</tr>
<tr>
<td>Creatinine (HPLC; mg/dl)</td>
<td>165.2 ± 14.6a</td>
<td>115.2 ± 7.5a,b</td>
<td>194.3 ± 21.9a,b</td>
<td>196.1 ± 34.2a,b</td>
</tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>103 ± 2.7a</td>
<td>129.8 ± 40a,b</td>
<td>88.5 ± 13.9b</td>
<td>88.5 ± 13.9b</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>112.8 ± 9.3a</td>
<td>83.5 ± 14.2b</td>
<td>80.9 ± 134.1ab</td>
<td>80.9 ± 134.1ab</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>263.5 ± 67.7c</td>
<td>51.1 ± 11.7</td>
<td>80.9 ± 134.1ab</td>
<td>80.9 ± 134.1ab</td>
</tr>
<tr>
<td>Albumin, 24-hour (μg)</td>
<td>111.6 ± 36.5</td>
<td>17.2 ± 6.0</td>
<td>241.8 ± 45.2cd</td>
<td>241.8 ± 45.2cd</td>
</tr>
</tbody>
</table>

Controls include C57BL/6 mice with and without the ob/ob mutation. ACR, albumin-creatinine ratio; ND, not done (sera from the 20- to 22-week-old C57BL/6 and C57BL/6 ob/ob mice had been exhausted).

aP < 0.001 versus WT of same gender and background strain.
bP < 0.001 versus C57BL/6 of same gender and ob mutation status.
cP < 0.01 versus WT of same gender and background strain.
dP < 0.01 versus C57BL/6 of same gender and ob mutation status.
eP < 0.05 versus C57BL/6 of same gender and ob mutation status.
BTBR ob/ob mice compared with WT littermates, although serum creatinine levels measured by both colorimetric and HPLC methods were not significantly different (Table 1).

The BTBR ob/ob mice developed albuminuria, with increased albumin-creatinine ratios measured in spot urine samples (Table 1, Figure 1). Elevated albuminuria was detectable as early as 8 weeks of age (Figure 1) and remained elevated thereafter, achieving a 10-fold difference by age 20 weeks. When timed urine collections were obtained, there was also a >10-fold increase in albumin excretion in both male and female BTBR ob/ob mice when compared with littermate controls at 20 weeks (Table 1). Mice were studied up to the age of 22 to 24 weeks, because around this age and beyond, there was greatly increased mortality for reasons yet to be identified.

Renal Structural Alterations
Obese, diabetic BTBR ob/ob mice exhibited renal hypertrophy compared with their BTBR WT littermates (Supplemental Table 1). Compared with C57BL/6 ob/ob mice, which were similarly obese, BTBR ob/ob mice had increased kidney weight, as did BTBR WT mice compared with C57BL/6 WT mice (Supplemental Table 1).

BTBR ob/ob mice develop renal lesions that consist of increasing glomerular mesangial matrix accumulation and are detectable histologically as early as 8 weeks of age (Figure 2). This mesangial matrix accumulation is either preceded or accompanied by episodes of mesangiolysis, because mesangiolysis can be detected in approximately 8% of glomeruli in tissue sections obtained from 8-week-old BTBR ob/ob mice (Figure 3, A and B). The degree of mesangiolysis increases with age, reaching an average of 24.5% of glomeruli exhibiting mesangiolysis at 16 weeks and 33.1% at 22 weeks of age in female mice (Figures 2K and 3, B through D). Male BTBR ob/ob mice had qualitatively similar degrees of mesangiolysis. In contrast, C57BL/6 ob/ob mice do not have markedly increased mesangial matrix or mesangiolysis (Figure 3E). Morphologically advanced glomerular abnormalities identified in both male and female BTBR ob/ob mice include diffuse and, rarely, nodular mesangial sclerosis (Figures 2, F and H, and 4), mesangiolysis (Figures 2K and 3, B through D), focal and mild interstitial fibrosis (Supplemental Figure 2), and, very focally, arteriolar hyalinosis (Figure 2H). Computer-aided morphometry, performed on collagen IV–immunostained tissue sections demonstrated significantly increased glomerular size and progressive accumulation of matrix in both male and female BTBR ob/ob mouse (Table 2, Supplemental Figure 3).

Measurement of glomerular capillary basement membrane thickness by electron microscopy showed an increase of 18% in BTBR ob/ob relative to BTBR WT at 20 weeks (181.4 ± 3.8 versus 152.9 ± 5.1 nm; n = 7; P < 0.001). Both electron microscopy and immunofluorescence confirmed the absence of immune deposits (Figure 4, Supplemental Figure 4).

Immunostaining for α-smooth muscle actin (α-SMA), a marker of mesangial cell activation, and for Mac-2–positive monocyte/macrophages revealed that both were increased significantly in BTBR ob/ob mice compared with WT littermate controls. Increased Mac-2–positive cells were first detected in the glomerular capillaries of 12-week-old BTBR ob/ob mice, later than when both podocyte loss and mesangiolysis were first detected, and after changes of marked mesangial matrix expansion were already present (Table 3). Measurement of α-SMA–positive mesangial cells within glomeruli was significantly increased in both male and female BTBR ob/ob mice at 22 weeks compared with WT littermates (3.70 ± 0.70 versus 0.17 ± 0.05% [P < 0.001] and 1.49 ± 0.46 versus 0.20 ± 0.06% [P < 0.05], respectively).

Importantly, BTBR ob/ob mice do not develop atherosclerosis (data not shown), and they do not develop hypertension. In fact, BTBR ob/ob mice are hypotensive compared with BTBR WT and heterozygous controls (Supplemental Figure 5), likely a direct consequence of leptin deficiency.16,17

Podocyte Number and Density
Podocyte number and density were measured at two time points, 8 and 20 weeks in BTBR WT and BTBR ob/ob mice and at 24 (n = 6) and 28 (n = 7) weeks in BTBR ob/ob mice only (Table 4). Podocyte number was reduced to an equivalent degree in BTBR ob/ob mice using both the Weibel and Sanden methods. Podocyte density was significantly reduced in BTBR ob/ob mice compared with BTBR WT mice at every time point studied (data using Sanden method illustrated in Table 4, Figure 5). The diminished density occurs in conjunction with increased glomerular volumes (0.530 ± 0.051 versus 0.270 ± 0.017 μm³ BTBR ob/ob versus BTBR WT at 20 weeks; P < 0.001). There was no increase in the number of apoptotic podocytes in the
BTBR ob/ob mice at either early (8 weeks) or late (20 weeks) time points compared with WT littermates, and only extremely rarely were any terminal deoxynucleotidyl transferase–mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL)-positive podocytes seen in any of the tissue sections examined (data not shown).

### Interstitial Fibrosis

Diffuse interstitial fibrosis was not detected using conventional histologic stains in any cohort studied, although focal and mild fibrosis was present in ≥12-week-old BTBR ob/ob mice (Supplemental Figure 2). Computer-aided morphometry performed on picrosirius red-stained slides to measure the degree of interstitial collagen accumulation showed significantly increased collagen accumulation in BTBR ob/ob mice at 24 weeks when compared with BTBR WT littermates (0.01000 ± 0.00180 versus 0.00086 ± 0.00025%; P < 0.001, percentage of cortical interstitial area picrosirius red positive, excluding perivascular areas).

### Comparisons with Controls

Comparisons of renal structural alterations achieved in BTBR and C57BL/6 mice treated with STZ (Supplemental Figure 6), C57BL/6 ob/ob mice (Figure 3E), and C57BLKS/J db/db (Figure 2L) with those in comparably aged BTBR ob/ob mice (Figure 2, D, F, and K) are illustrated in multiple...
The BTBR ob/ob mouse model of DN comes close to meeting all of the proposed criteria of the AMDCC (albuminuria, pathologic changes) and offers several important advantages compared with existing DN models. The most important of these is the degree to which it reproduces essential structural and functional features of human diabetic glomerular injury. Glomerular hypertrophy, marked expansion of mesangial matrix, mesangiolysis, capillary basement membrane thickening, and loss of podocytes each have been identified as characteristic features of diabetic glomerular injury in humans, and each is present in the BTBR ob/ob model. The functional consequence of these changes in humans—marked proteinuria—also is present in this mouse model with a 10-fold increase in urinary protein excretion compared with controls.

Second, the model is robust and progressive: BTBR ob/ob mice uniformly develop features of DN and do so in a predictable time course in which podocyte loss is already detectable by 8 weeks of age and persists throughout the disease. The basis for podocyte loss was not established in this study, although the lack of significant apoptosis detected by TUNEL staining suggests other means of cell death or detachment are likely important. Studies are under way to investigate the mechanism of podocyte loss in these mice. Significant proteinuria is detectable as early as 8 weeks of age, corresponding with detectable podocyte loss at 8 weeks of age and persists throughout the disease. The basis for podocyte loss was not established in this study, although the lack of significant apoptosis detected by TUNEL staining suggests other means of cell death or detachment are likely important. Studies are under way to investigate the mechanism of podocyte loss in these mice. Significant proteinuria is detectable as early as 8 weeks of age, corresponding with detectable podocyte loss, although it can be detected in some mice at even earlier ages, albeit without achieving statistical significance, when comparing 4-week-old cohorts with controls. Mesangiolysis is also an early feature of the disease, detectable in approximately 10% of glomeruli at 8 weeks of age, and coincides with significant proteinuria.
with detectable expansion of the mesangial matrix. These mesangial alterations are progressive. Many murine models of DN, such as STZ-induced DN, develop mild to moderate mesangial expansion and hence are good models of lesions occurring early in the course of human DN; the BTBR ob/ob mouse is among the very few models in which pronounced mesangial

Table 2. BTBR ob/ob mice have significantly increased accumulations of mesangial matrix

<table>
<thead>
<tr>
<th>Age (weeks)</th>
<th>BTBR WT</th>
<th>BTBR ob/ob</th>
<th>C57BL/6 WT</th>
<th>C57BL/6 ob/ob</th>
<th>C57BLKS/J db/+</th>
<th>C57BLKS/J db/db</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>13.20 ± 0.60</td>
<td>16.70 ± 0.90a</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>12</td>
<td>5.10 ± 1.90</td>
<td>13.10 ± 0.02a</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>16</td>
<td>11.70 ± 1.40</td>
<td>23.70 ± 1.40b</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>20</td>
<td>7.90 ± 1.60</td>
<td>18.30 ± 1.50b</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>22</td>
<td>6.70 ± 1.50</td>
<td>18.30 ± 1.50b,cd</td>
<td>7.00 ± 0.16</td>
<td>6.95 ± 0.53</td>
<td>6.40 ± 2.50</td>
<td>7.80 ± 3.90</td>
</tr>
<tr>
<td>24</td>
<td>11.00 ± 2.20</td>
<td>19.70 ± 1.20f</td>
<td>ND</td>
<td>ND</td>
<td>4.90 ± 0.40</td>
<td>9.80 ± 2.70</td>
</tr>
</tbody>
</table>

The percentage of mesangial matrix within glomerular tuft area was determined by collagen IV–positive matrix in male BTBR WT, BTBR ob/ob, C57BL/6 WT, C57BL/6 ob/ob, C57BL/6 KS db/+,, and C57BL/6 KS db/db mice at the time points shown (n = 6). Significant accumulation of mesangial matrix in BTBR ob/ob mice is seen as early as 8 weeks of age. ND, not done.

Table 3. BTBR ob/ob mice have significantly more Mac-2–positive cells per glomerulus compared with WT littermates starting at approximately 12 weeks of age, after the time point when mesangiolysis is seen in a number of glomeruli

<table>
<thead>
<tr>
<th>Age (weeks)</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTBR WT</td>
<td>BTBR ob/ob</td>
<td>BTBR WT</td>
</tr>
<tr>
<td>4</td>
<td>0.62 ± 0.17</td>
<td>0.99 ± 0.21</td>
</tr>
<tr>
<td>8</td>
<td>0.77 ± 0.10</td>
<td>1.41 ± 0.17</td>
</tr>
<tr>
<td>12</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>20</td>
<td>0.77 ± 0.11</td>
<td>1.40 ± 0.28</td>
</tr>
<tr>
<td>22</td>
<td>0.75 ± 0.06</td>
<td>4.30 ± 0.79a</td>
</tr>
</tbody>
</table>

Fourth, there is increasing recognition of an inflammatory component in human and experimental DN, usually characterized by an influx of monocytes/macrophages. Progression of DN in the BTBR ob/ob mouse is also characterized by an influx of monocytes/macrophages. As in the hu-
man lesions, it is not clear whether subpopulations of these cells change during the course of the disease and whether subsets of monocytes/macrophages mediate specific injury processes such as mesangiolysis or contribute to progressive injury, repair, or both. Finally, the absence of hypertension in this model allows identification of mediators of DN independent of the confounding effects of coexisting hypertension as may occur in other models.

The BTBR ob/ob model compares favorably with other leading murine models of advanced DN—those based on endothelial nitric oxide synthase deficiency (eNOS<sup>−/−</sup>) in which diabetes is induced by STZ or by introducing the db/db mutation. These models, unlike STZ-induced DN in other strains, have in common the features of mesangiolysis. We hypothesize, on the basis of this finding and the common finding of mesangiolysis in advanced human DN, that mesangiolysis is an essential injury for the development of advanced DN. Two key differences between the BTBR and eNOS<sup>−/−</sup> models are that the BTBR leptin-deficient model offers the potential of reversibility of established DN lesions with administration of leptin that is currently lacking in murine models in which eNOS is constitutively absent and that the BTBR model lacks the low level of confounding endothelial injury and tendency to thrombogenicity that has been reported in eNOS<sup>−/−</sup> mice. It has been reported that mesangiolysis and mesangial nodular lesions can be prevented by insulin or anti-hypertensive therapy in eNOS<sup>−/−</sup> mice made diabetic by STZ. The possibility that the unique susceptibility to DN in BTBR ob/ob mice may be due to endothelial dysfunction akin to the defects resulting from eNOS deficiency is being explored.

Like any animal model system, there also are limitations to the BTBR ob/ob model. Most important, this is a strain-dependent model system, as demonstrated by the striking differences between diabetic insulin-resistant BTBR ob/ob mice and similarly obese but nondiabetic C57BL/6 ob/ob mice. BTBR is not a strain familiar to many investigators; however, as differences in strain (and genetic background in humans) have become increasingly recognized as critical determinants of susceptibility to diabetes and nephropathy, this unique background may also be something of an advantage. It has been recognized that the most widely used mouse strain for chemical induction of diabetes by STZ, C57BL/6, is in fact poorly disposed to develop DN. A series of genetic studies of BTBR ob/ob mice have identified the genes responsible for insulin resistance and further have identified networks of gene expression in pancreas, adipose tissue, liver, skeletal muscle, and brain that mediate various metabolic abnormalities consequent to diabetes. These studies have the potential to provide a basis for understanding pathogenic events in the development of DN that may involve extrarenal sites and systemic perturbations consequent to diabetes and identify genetic differences between BTBR ob/ob mice and DN-resistant mice that may help elucidate critical mechanisms underlying DN. As an example, one gene identified by this analysis, SORCS1, has recently been identified as one of many genes where variants contribute to diabetes risk and glycemic control in humans, further demonstrating the utility of this model for understanding human disease.

A second potential limitation is that this is a mouse model dependent on both strain (BTBR) and leptin deficiency. Overt leptin deficiency is not a characteristic of human diabetes, although the obesity commonly encountered in patients with type 2 diabetes is associated with leptin resistance. This places limits on the overall similarity of leptin-deficient mouse models to the human condition. Nonetheless, the similarity of the diabetic complications that develop in this model to those in humans establishes it as a valuable tool to investigate DN and other complications. A third important limitation is that al-

---

### Table 4. BTBR ob/ob mice have decreased podocyte number and podocyte density when compared to their WT littermates, apparent as early as 8 weeks of age, reaching statistical significance at 20 weeks of age

<table>
<thead>
<tr>
<th>Parameter</th>
<th>BTBR WT</th>
<th>BTBR ob/ob</th>
</tr>
</thead>
<tbody>
<tr>
<td>Podocyte no. (per glomerular tuft)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 weeks</td>
<td>85.44 ± 12.61</td>
<td>69.57 ± 6.50</td>
</tr>
<tr>
<td>20 weeks</td>
<td>96.28 ± 6.70</td>
<td>70.77 ± 6.41*</td>
</tr>
<tr>
<td>Glomerular volume (×10&lt;sup&gt;6&lt;/sup&gt; μm&lt;sup&gt;3&lt;/sup&gt;)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 weeks</td>
<td>0.210 ± 0.014</td>
<td>0.290 ± 0.023</td>
</tr>
<tr>
<td>20 weeks</td>
<td>0.270 ± 0.017</td>
<td>0.530 ± 0.051&lt;sup&gt;a,c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Podocyte density (cell number/100 μm&lt;sup&gt;3&lt;/sup&gt; glomerular volume)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 weeks</td>
<td>4.01 ± 0.46</td>
<td>2.49 ± 0.28&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>20 weeks</td>
<td>3.57 ± 0.33</td>
<td>1.35 ± 0.10&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>24 weeks</td>
<td>ND</td>
<td>1.20 ± 0.15&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>28 weeks</td>
<td>ND</td>
<td>0.99 ± 0.13&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

The BTBR ob/ob mice also have significantly increased glomerular volume (n = 5 to 7 per group). ND, not done.

<sup>a</sup>P < 0.05, <sup>b</sup>P < 0.001 versus age-matched BTBR WT littermates.

<sup>c</sup>P < 0.001 versus 8-week BTBR ob/ob and WT.

<sup>d</sup>P < 0.001 versus 20-week BTBR WT.

---

**Figure 5.** BTBR ob/ob mice have reduced podocyte number. (A and B) There is a reduction in podocyte number, assessed by WT-1 staining, in BTBR ob/ob (A) compared with BTBR WT (B) mice.

---

**www.jasn.org**

---

**BASIC RESEARCH**

---


---

**DN in BTBR ob/ob Mice**

---

1539
though the glomerular alterations strongly model those of human DN, the degree of interstitial fibrosis achieved at the time points studied, although measurably different from controls, is histologically modest overall. Concomitant measures of serum BUN and creatinine have also failed to suggest significant renal insufficiency. A likely basis for this lack of progressive renal insufficiency in this model despite marked glomerular changes is that measurable loss of renal function and interstitial fibrosis are processes occurring later in the disease course than the glomerulopathy. Although fibrotic changes are present at 20 to 22 weeks, this is an insufficient period for these changes to become advanced or for the most advanced changes of global glomerulosclerosis to develop. We may also detect loss of renal function when we are able to use the more sensitive direct measure of GFR rather than rely on a relatively insensitive measure of serum creatinine for this purpose.

Despite the susceptibility to diabetes and development of DN in BTBR ob/ob mice, studies by the group of Attie et al.13 have shown that lean BTBR mice are normally insulin resistant (high circulating insulin levels) but normoglycemic. These mice are resistant to STZ-induced hyperglycemia, requiring much higher dosages to achieve similar blood glucose levels than STZ-treated C57BL/6 mice, a finding that was confirmed in this study. Hyperglycemic BTBR WT mice developed only modest manifestations of DN, after 30 weeks of hyperglycemia. The unique susceptibility of BTBR ob/ob mice toward developing diabetic complications requires both the BTBR genetic background and metabolic abnormalities conferred by the ob/ob mutation.

We anticipate the BTBR ob/ob mouse will prove an attractive model for study because unlike most other murine models of DN, not only do they develop lesions similar to human DN, but also there is preliminary evidence that complications in other organ systems that are typically encountered in humans with diabetes, such as cardiomyopathy26 and liver disease (data not shown), develop in this model. As a model of leptin deficiency (unlike the db/db leptin receptor–deficient mouse), these mice offer the potential for reversal of disease with leptin deficiency (unlike the db/db leptin receptor–deficient mouse), these mice offer the potential for reversal of disease with leptin administration. Preliminary studies by our laboratory indicate regression of nephropathy can be achieved by this approach; these studies will be the subject of a separate report.

**CONCISE METHODS**

**Animals**

The experimental protocol was reviewed and approved by the Animal Care Committee of the University of Washington in Seattle. The establishment of BTBR ob/ob mice has been previously described.11,12 Breeding pairs of BTBR WT, BTBR ob/ob heterozygotes [BTBRob+/--; BTBR.V(B6)-Lep<sup>ab</sup>/Wisc; stock no. 004824)], C57BLKS/J Lepr<sup>ab</sup> (C57BLKS/J <i>db/db</i>), and C57BL/6J ob/ob mice were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained in a specific pathogen–free facility with a 12-hour light cycle and with free access to standard diet and water. Male and female BTBR ob/ob, BTBR WT, C57BLKS/J <i>db/db</i>, and C57BLKS/J <i>db/db</i> littermate mice were killed serially at 4, 8, 12, 16, 20, 22, and 24 weeks of age (n = 6 each group). A group of 28-week-old BTBR ob/ob mice (n = 7) were also studied. Male and female C57BL/6J ob/ob and WT littermate mice were killed at 22 and 24 weeks of age (n = 6).

As additional controls, male BTBR and C57BL/6J mice were made diabetic by five daily injections of STZ (80 and 50 mg/kg, respectively) beginning at 8 weeks of age and killed at 38 weeks of age (n = 8 BTBR) and 45 weeks of age (n = 8 C57BL/6J), after 30 and 37 weeks of hyperglycemia, respectively. Control mice received five daily injections of citrate. The higher dosage of STZ used in BTBR mice was established in pilot studies conducted to determine the optimal dosage of STZ required to induce diabetes. BTBR WT mice received five daily STZ injections of 40, 50, 60, or 80 mg/kg (n = 3). The mice had an average starting blood glucose level of 130.3 ± 4.2 mg/dl, and this was not appreciably increased by the 40, 50, or 60 mg/kg STZ injections (average blood glucose levels of 100.7 ± 45.7, 130.7 ± 18.8, and 156.0 ± 3.8 mg/dl, respectively), whereas the 80-mg/kg dose resulted in an average blood glucose level of 287.7 ± 43.9 mg/dl after 3 weeks. C57BL/6J mice treated with five daily doses of STZ at 50 mg/kg achieved blood glucose levels of 342.3 ± 22.3 mg/dl in the same pilot study.

**Blood Chemistry**

Blood samples were obtained by saphenous vein puncture and at the time when mice were killed. Blood glucose levels were monitored using a Freestyle Blood Glucose Monitor (Abbott Diabetes Care, Alameda, CA).

BUN was measured using the QuantiChrom Urea Assay Kit (BioAssay Systems, Hayward CA). Serum creatinine levels were measured by an HPLC-based method at the Yale University Mouse Metabolic Phenotyping Center metabolic testing core.

**Urine Measurements**

Timed (12 hour) urine and spot urine samples were collected from individual mice before being killed. Urine was collected during the evening dark cycle, with the mice having access to water but not food. Urinary albumin was measured using the Albuwell M Murine ELISA kit (Exocell, Philadelphia PA), and urinary creatinine was measured with the Creatinine Companion kit (Exocell). Total albumin measured in 12-hour samples was multiplied by 2 to obtain a 24-hour protein excretion rate.

**BP Measurement**

BPs were measured using the Coda-6 VPR tail-cuff system (Kent Scientific, Torrington, CT)27,28 on conscious mice, as described previously,29 before mice were killed at the time points described already (n = 6 each group).

**Histologic Analysis**

Kidneys and other organs were obtained from BTBR WT, BTBR ob/ob, C57BL/6J ob/ob, C57BL/6J WT, C57BLKS/J <i>db/db</i>, C57BLKS/J <i>db/db</i>+, and STZ-treated BTBR and C57BL/6J mice at each of the previously indicated time points, and portions were immersion-fixed in 10% neutral-buffered formalin and in methyl Carnoy fixative. Tissues were embedded in paraffin using standard methods; sectioned; and stained with silver methenamine, periodic acid–Schiff, hematoxylin and eosin, and picrosirius red reagents. Selected tissues fixed in ½ strength Karnovsky solution were processed, sectioned, and examined by electron
microscopy according to standard protocols. In cases examined by this technique, a series of 10 photographs were taken at ×12,000 magnification, a grid was overlaid on the photograph and basement membrane thickness was measured at points where it intersected with the grid.

**Immunohistochemistry and TUNEL**

Four-micrometer sections of formalin or methyl Carnoy–fixed, paraffin-embedded tissue were immunostained as described previously.30,31 The antibodies used were (1) rat anti–Mac-2 (Cedarlane; Hornby, Ontario, Canada)32 to detect infiltrating monocytes/macrophages; (2) mouse anti–α-SMA, clone 1A4 (Sigma, St. Louis, MO); (3) rabbit anti–WT-1 (Santa Cruz Biotechnology, Santa Cruz, CA) to mark podocyte nuclei; (4) rat anti–KI-67, clone Tec3 (Dako, Carpinteria, CA), as a measure of cell proliferation; and (5) rabbit anti–collagen IV (Southern Biotechnology, Birmingham, AL). Negative controls for immunohistochemistry included both substitution of the primary antibody with an isotype-matched irrelevant Ig or antiserum from the same species and substitution with PBS. Immunofluorescence was performed on frozen tissue sections to detect the presence of IgG, IgA, IgM, and C3 as described previously.33 Apoptotic cells were detected using the ApopTag Plus kit (Chemicon Int., Temecula, CA) according to the manufacturer’s instructions.

**Quantitative Analysis of Glomerular and Interstitial Lesions**

For each animal, 20 0.1-mm² section areas were randomly photographed under ×400 magnification, and the glomerular cross-sectional area and degree of glomerular matrix accumulation (collagen IV expression and silver methenamine stain), mesangial actin expression, and area occupied by α-SMA–positive activated mesangial cells were quantified by computer image analysis (ImagePro Plus image analysis software) as described previously.30,34 Mac-2–positive monocyte/macrophages within glomeruli were counted in a minimum of 50 glomerular cross-sections and expressed as average number of cells per glomerular area. Silver methenamine–stained histologic sections were examined in a blinded manner, and the number of glomeruli exhibiting mesangiolysis (defined as dissolution with areas of lucency of mesangial regions that normally exhibit compact silver staining matrix and/or marked microaneurysmal dilation of adjacent glomerular capillaries) in an entire cross-sectional kidney section was counted. Slides stained with picrosirius red were photographed under polarized light to achieve maximal brightness, and the percentage of positive interstitial staining was quantified using ImagePro Plus software.

**Enumeration of Podocytes**

Podocyte counting was performed on 3-μm sections of formalin-fixed tissue immunostained with a marker of podocyte nuclei (WT-1). Fifty stained glomerular sections were digitally photographed, and the images were imported into the ImagePro Plus software and analyzed morphometrically. The estimation of the average number of podocytes per glomerulus is then determined by the stereologic method published by Weibel,35 which is based on determining density of podocytes (identified by their WT-1 expression in nuclei) per glomerulus in histologic slides, and the multiplication of this density by the measured glomerular volume to obtain podocyte cell number, as used by others.36–38

Because of published concerns by others that this method may overestimate absolute podocyte numbers,39 a second approach to measure podocyte number and podocyte density was also used. We followed the method of Sanden et al.10 by using WT-1–stained nuclei to enumerate podocytes in kidney tissue sections of uneven thickness (3 and 9 μm). After glomerular volumes were calculated, the counted podocyte nuclei were used to determine podocyte density, a measure that overcomes the problem of cell counts in glomeruli of unequal sizes and that may be a better measure of podocyte integrity.7,41

**Statistical Analysis**

All values are expressed as the mean ± SEM. Analysis was performed using InStat StatView for Windows (GraphPad Software, La Jolla, CA), using one-way ANOVA and the Tukey-Kramer Multiple Comparisons Test or the unpaired two-tailed t test to determine P values.

**ACKNOWLEDGMENTS**

This work was supported by an National Institute of Diabetes and Digestive and Kidney Diseases Mouse Metabolic Phenotypic Center’s MICROMouse funding program (grant DK076169) and by National Institutes of Health grant DK076126 to the Seattle Mouse Metabolic Phenotyping Center, and by National Institutes of Health grants DK66369 and DKS8037 to A.D.A. Measurement of creatinine by HPLC was performed by the Yale MMPC Analytic Core facility, supported in part by National Institute of Diabetes and Digestive and Kidney Diseases grant U24DK76169.

Portions of this work were presented at the annual meetings of the American Society of Nephrology, November 14 through 19, 2006, San Diego, CA; and November 5 through 9, 2008, Philadelphia, PA.

**DISCLOSURES**

None.

**REFERENCES**


See related editorial, “Progress in Progression?” on pages 1414–1416.

Supplemental information for this article is available online at http://www.jasn.org/.